CEL-SCI Announces Exclusive Sales, Marketing and Distribution Agreement for Its Investigational Cancer Therapy Multikine for Argentina and Venezuela

CEL-SCI Corporation

today announced that it has entered into an exclusive Sales, Marketing and Distribution agreement with IDC-GP Pharm LLC under which CEL-SCI has granted IDC-GP Pharm an exclusive license to market and distribute the Company's investigational cancer therapy, Multikine in the countries of Argentina and Venezuela. IDC-GP Pharm is a Joint Venture between two groups of experienced pharmaceutical entrepreneurs with expertise in the registration and commercialization of pharmaceutical products in South America, among other regions. One of these two groups represents former employees of a large pharmaceutical company, while the other group is GP Pharm , headquartered in Barcelona, Spain, with operations in each major country in Latin America either directly or through local partners. CEL-SCI already has existing licensing agreements for Multikine with Teva Pharmaceuticals Industries Ltd.

, Orient Europharma Co. Ltd. and Byron Pharmaceuticals.